Eli Lilly GLP-1 Drugs Drive Explosive Revenue Growth and Pricing Adjustments

28 days ago

SPEAKER_03

"We reported global sales, which surpassed Keytruda to becoming the best selling drug in the world, actually the best selling drug in the world of all time in Q2 this year. How much did it make in Q2? We, uh, $8.1 billion in revenue and growing at 80%. And originally it was priced around $1,000, now down to $499, with plans to push it further lower, and eventually moving to an oral pill format next year."

The CEO discusses the remarkable performance of Eli Lilly's GLP-1 drugs, noting an $8.1 billion revenue in Q2 with 80% growth, pricing cuts from $1,000 to $499, and plans to launch an oral pill version next year. This commentary underscores the company's strong product traction, market leadership, and potential for further growth as pricing adjusts to broader market access.

Related Stocks